Literature DB >> 8837222

Urinary immunoreactive brain natriuretic peptide in patients with renal disease.

K Totsune1, K Takahashi, F Satoh, M Sone, M Ohneda, C Satoh, O Murakami, T Mouri.   

Abstract

Urinary immunoreactive brain natriuretic peptide (BNP) was studied by radioimmunoassay in patients with renal disease. Urinary immunoreactive human BNP excretion measured in 11 normal subjects was 3.82 +/- 0.62 pmol/day (mean +/- SEM). Significantly increased 24-h urinary secretion of immunoreactive human BNP was noted in patients with chronic renal failure (11.07 +/- 1.73 pmol/day, n = 9, P < 0.05 to normal subjects). A significant correlation was noted between 24-h urinary excretion of immunoreactive human BNP and creatinine clearance in patients with various renal diseases (r = -0.43, P < 0.01, n = 45). Gel chromatography of the urine extracts obtained from normal subjects and patients with chronic renal failure showed multiple immunoreactive peaks; two eluting earlier, one in the position of human BNP-32 and others eluting later. Reverse-phase high-performance liquid chromatography of the urine extracts showed a peak in the position of human BNP-32 and a peak eluting earlier. These findings indicate that: (1) immunoreactive human BNP is present in human urine; (2) urinary immunoreactive human BNP consists of multiple components, i.e., human BNP-32 itself or a substance very similar to it, smaller molecular forms which are probably metabolic products of human BNP-32, and larger molecular forms; and (3) 24-h urinary excretion of immunoreactive human BNP is increased in patients with renal dysfunction.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8837222     DOI: 10.1016/0167-0115(96)00035-3

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  5 in total

Review 1.  Structure, signaling mechanism and regulation of the natriuretic peptide receptor guanylate cyclase.

Authors:  Kunio S Misono; John S Philo; Tsutomu Arakawa; Craig M Ogata; Yue Qiu; Haruo Ogawa; Howard S Young
Journal:  FEBS J       Date:  2011-04-07       Impact factor: 5.542

2.  Elevated plasma concentrations of atrial and brain natriuretic peptide in type 1 diabetic subjects.

Authors:  K McKenna; D Smith; M Sherlock; K Moore; E O'Brien; W Tormey; C J Thompson
Journal:  Ir J Med Sci       Date:  2005 Jul-Sep       Impact factor: 1.568

Review 3.  B-type natriuretic peptide and renal disease.

Authors:  Peter A McCullough; Keisha R Sandberg
Journal:  Heart Fail Rev       Date:  2003-10       Impact factor: 4.214

4.  Reversibly bound chloride in the atrial natriuretic peptide receptor hormone-binding domain: possible allosteric regulation and a conserved structural motif for the chloride-binding site.

Authors:  Haruo Ogawa; Yue Qiu; John S Philo; Tsutomu Arakawa; Craig M Ogata; Kunio S Misono
Journal:  Protein Sci       Date:  2010-03       Impact factor: 6.725

5.  N-terminal fragment of probrain natriuretic peptide is associated with diabetes microvascular complications in type 2 diabetes.

Authors:  Kumiko Hamano; Ikue Nakadaira; Jun Suzuki; Megumi Gonai
Journal:  Vasc Health Risk Manag       Date:  2014-10-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.